AlphaCrest Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

AlphaCrest Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-14,484	Closed	-$334K	–	1375
2021 Q1	$334K	Sell	14,484 -4,339	-23%	-$121K	0.02%	974
2020 Q4	$465K	Buy	18,823 +10,632	+130%	+$352K	0.04%	688
2020 Q3	$340K	Buy	8,191 +2,137	+35%	+$98.2K	0.04%	797
2020 Q2	$290K	Buy	6,054 +620	+11%	+$47.9K	0.05%	650
2020 Q1	$342K	Buy	5,434 +393	+8%	+$35.3K	0.04%	741
2019 Q4	$625K	Sell	5,041 -4,720	-48%	-$423K	0.05%	636
2019 Q3	$648K	Buy	+9,761	New	+$655K	0.04%	790

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

AlphaCrest Capital Management's ICPT Position: Q2 2021 in Review

AlphaCrest Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2021, closing a stake of 14,484 shares — an estimated $334K sold.

AlphaCrest Capital Management first reported a position in ICPT in Q3 2019 and held it in 7 quarters. The position peaked at $648K in Q3 2019. 129 funds tracked by Wall St. Rank hold ICPT as of Q2 2021.

AlphaCrest Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
AlphaCrest Capital Management sold 14,484 Intercept Pharmaceuticals, Inc. shares in Q2 2021, an estimated $334K.
AlphaCrest Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2019 and held it in 7 quarters.
AlphaCrest Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $648K in Q3 2019.
129 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2021.

Based on AlphaCrest Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.